Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy

High BMI is a well-known risk factor for the development and recurrence of several solid tumours, including CRC. Obesity is associated with increased levels of vascular endothelial growth factor (VEGF). Bevacizumab is the main targeted therapy for inhibiting tumour angiogenesis by blocking the VEGF/...

Descripción completa

Detalles Bibliográficos
Autores principales: Faruk Aykan, N., Yildiz, Ibrahim, Sen, Fatma, Kilic, Leyla, Keskin, Serkan, Ciftci, Rumeysa, Karabulut, Senem, Sakar, Burak, Disci, Rian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755215/
https://www.ncbi.nlm.nih.gov/pubmed/23921648
http://dx.doi.org/10.1007/s12032-013-0679-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755215/
https://www.ncbi.nlm.nih.gov/pubmed/23921648
http://dx.doi.org/10.1007/s12032-013-0679-4

Ejemplares similares